0

Exelixis Announces Positive Phase 3 Results In Patients With Kidney Cancer

Today Exelixis (NASDAQ:EXEL) announced positive results in their phase 3 study for patients with Renal Cell Carcinoma — also known as kidney cancer. The phase 3 trial, known as the Meteor trial, recruited up to 658 patients with metastatic kidney… Continue Reading

0

Ohr Pharmaceuticals Obtains Positive Phase 2 Results For Retinal Vein Occlusion

(BiotechPickList) – Shares of Ohr Pharmaceuticals (NASDAQ:OHRP) closed the day up 67% after announcing positive phase 2 results for treatment of Retinal Vein Occlusion using a combination therapy. The phase 2 trial recruited 20 naive (not previously treated) patients with macular… Continue Reading

0

Johnson & Johnson Psoriasis Drug Makes It Out On Top In Phase 2b Trial

(BiotechPickList) –  Johnson & Johnson (NYSE:JNJ) announced today that it has successfully completed a phase IIb psoriasis study using its IL-23 drug blocker. The IL-23 blocker is also known as guselkumab and has done quite well to date for patients… Continue Reading

0

Arrowhead Doses First Patient For Rare Liver Disease

(BiotechPickList) – Arrowhead Research Corp (NASDAQ:ARWR) today announced that is has dosed the first patient in a phase 1 clinical trial for a rare liver disease. The drug being used in this phase 1 trial is known as ARC-AAT and… Continue Reading

0

Vanda Pharmaceuticals Announces Positive Results In Schizophrenia Patients Who Relapse

(BiotechPickList) – Today Vanda Pharmacduticals (NASDAQ:VNDA) announced positive results from a Relapse prevention study in patients with Schizophrenia. The trial is known as the REPRIEVE clinical study which was a randomized placebo control study. One thing to note was that… Continue Reading

0

Biomarin Posts Positive Phase 2 Results for Its Dwarfism Drug

(BiotechPickList) – Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) are up about 6% in after hours trade after the company reported positive phase 2 results in children with Achondroplasia — also known as the most common form of human dwarfism. The company’s… Continue Reading

0

FDA Panel Backs New Class Of Medicine For High Cholesterol Drug

Today both Sanofi (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) won over an FDA panel who agreed to back a cholesterol lowering drug that could possibly end up reducing the risk of patients getting a heart attack. The panel voted 13-3 ,… Continue Reading

0

Rxi Pharmaceuticals: Multiple News This Week And Beyond

It has been a busy few weeks for Rxi Pharmaceuticals (NASDAQ:RXII) as it has released multiple news sources that has garnered a lot of volume over the many trade sessions. For starters Rxi announced a public offering on May 28,… Continue Reading

0

Inovio Pharmaceuticals Partners With GeneOne Life Science For MERS Virus

On May 27, 2015  Inovio Pharmaceuticals (NASDAQ:INO) announced that it had entered into a partnership with GeneOne Life Science for MERS immunotherapy development. MERS is a lethal virus in the Middle East that kills at least 40% of those who are… Continue Reading

0

Celgene Announces Positive Phase 2 Data In Patients With Crohn’s Disease

Today Celgene (NASDAQ:CELG) announced positive phase 2 results for their Crohn’s Disease study. This data was presented at the Digestive Disease Week — DDW — in Washington D.C. This trial was run as a double-blind placebo controlled trial in which… Continue Reading